Bortezomib will increase the stage or effect of flibanserin by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep an eye on. Elevated flibanserin adverse outcomes may arise if coadministered with many weak CYP3A4 inhibitors. B: Can be appropriate. Either animal scientific tests show no danger but human scientific studies not available https://finnzfjmq.blogerus.com/49330511/dup-747-fundamentals-explained